Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety/interaction claims that reflect label-supported increased bleeding risk with concomitant antithrombotic agents are aligned, but the response includes a potentially label-noncompliant prescriptive instruction ('not recommended') regarding aspirin with Vascepa that is not clearly stated in the provided label excerpts.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to treat high triglycerides.
Supported by 1 INDICATIONS AND USAGE (TG-related indications).
Taking aspirin with Vascepa can increase the risk of bleeding.
Supported by 5 WARNINGS AND PRECAUTIONS (5.3 Bleeding) (greater incidence with concomitant antithrombotic medications such as aspirin).
Warfarin can increase the risk of bleeding when taken with Vascepa.
Supported by 5 WARNINGS AND PRECAUTIONS (5.3 Bleeding) and 7 DRUG INTERACTIONS (7.1) (monitoring increased bleeding risk with anticoagulants; antithrombotic medications including warfarin).
Clopidogrel can increase the risk of bleeding when taken with Vascepa.
Supported by 5 WARNINGS AND PRECAUTIONS (5.3 Bleeding) and 7 DRUG INTERACTIONS (7.1) (antithrombotic medications such as clopidogrel; monitoring for bleeding).
Unsupported Statements
Taking aspirin with Vascepa can increase the risk of gastrointestinal bleeding.
Provided label excerpts discuss overall bleeding risk with concomitant antithrombotic medications but do not specify gastrointestinal bleeding.
Taking aspirin with Vascepa can increase the risk of intracranial hemorrhage.
Provided label excerpts discuss bleeding in general but do not specify intracranial hemorrhage.
Acetaminophen (Tylenol) is described as a safe and effective alternative to aspirin for headaches.
No acetaminophen or headache/alternative guidance is present in the provided Vascepa label excerpts.
NSAIDs such as ibuprofen and naproxen can increase the risk of bleeding when taken with Vascepa.
Provided label excerpts mention concomitant anticoagulants/antiplatelet agents (e.g., aspirin, clopidogrel, warfarin) and monitoring for bleeding, but do not mention NSAIDs.
Aspirin can increase the risk of bleeding when taken with certain medications.
This is a general aspirin claim not supported by the provided Vascepa label excerpts (no general aspirin statement provided).
Dr. Steven Nissen states that the risk of bleeding with aspirin and Vascepa is a concern, especially in patients taking anticoagulant medications.
Speaker/attribution content is not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
The response does not reflect the label instruction to monitor patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents for bleeding (instead stating a blanket 'not recommended').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label supports increased bleeding risk with concomitant antithrombotic medications and monitoring for bleeding, but the blanket 'not recommended to take aspirin with Vascepa' may misrepresent the label’s exact management language, potentially affecting appropriate risk-benefit decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Overly prescriptive instruction ('not recommended') regarding aspirin coadministration that may exceed what is stated in the provided label language (label emphasizes increased bleeding risk and monitoring).
Suggested Improvement
Replace the blanket prohibition with label-consistent wording, e.g., that VASCEPA is associated with increased bleeding risk and that patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents (such as aspirin) should be monitored for bleeding, without asserting an explicit recommendation against use.